{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T21:56:18Z","timestamp":1792446978419,"version":"4.5.0"},"reference-count":95,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T00:00:00Z","timestamp":1730937600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pathogens"],"abstract":"<jats:p>Pseudomonas aeruginosa is causing increasing concern among clinicians due to its high mortality and resistance rates. This bacterium is responsible for various infections, especially in hospital settings, affecting some of the most vulnerable patients. Pseudomonas aeruginosa has developed resistance through multiple mechanisms, making treatment challenging. Diagnostic techniques are evolving, with rapid testing systems providing results within 4\u20136 h. New antimicrobial agents are continuously being developed, offering potential solutions to these complex clinical decisions. This article provides a review of the epidemiology, at-risk populations, resistance mechanisms, and diagnostic and treatment options for Pseudomonas aeruginosa.<\/jats:p>","DOI":"10.3390\/pathogens13110975","type":"journal-article","created":{"date-parts":[[2024,11,7]],"date-time":"2024-11-07T12:12:13Z","timestamp":1730981533000},"page":"975","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":73,"title":["Multidrug Resistant Pseudomonas aeruginosa in Clinical Settings: A Review of Resistance Mechanisms and Treatment Strategies"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-2330-8903","authenticated-orcid":false,"given":"Beth","family":"Schwartz","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Henry Ford St. John Hospital, Detroit, MI 48236, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Klamer","sequence":"additional","affiliation":[{"name":"Thomas Mackey Center for Infectious Disease, Henry Ford St. John Hospital, Detroit, MI 48201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Zimmerman","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Science, Wayne State University, Henry Ford St. John Hospital, Detroit, MI 48201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8729-7710","authenticated-orcid":false,"given":"Pramodini B.","family":"Kale-Pradhan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Practice, Eugene Applebaum College of Pharmacy and Health Science, Wayne State University, Henry Ford St. John Hospital, Detroit, MI 48201, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6326-0908","authenticated-orcid":false,"given":"Ashish","family":"Bhargava","sequence":"additional","affiliation":[{"name":"Thomas Mackey Center for Infectious Disease, Henry Ford St. John Hospital, Detroit, MI 48201, USA"},{"name":"School of Medicine, Wayne State University, Detroit, MI 48021, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,11,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.jhin.2019.06.005","article-title":"Incremental Clinical and Economic Burden of Suspected Respiratory Infections Due to Multi-Drug-Resistant Pseudomonas aeruginosa in the United States","volume":"103","author":"Tabak","year":"2019","journal-title":"J. Hosp. Infect."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1078\/1438-4639-00085","article-title":"Capability of Mucoid Pseudomonas aeruginosa to Survive in Chlorinated Water","volume":"204","author":"Grobe","year":"2001","journal-title":"Int. J. Hyg. Environ. Health"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jenvman.2010.09.001","article-title":"Antibiotic-Resistant Pseudomonas aeruginosa from Hospital Wastewater and Superficial Water: Are They Genetically Related?","volume":"92","author":"Fuentefria","year":"2011","journal-title":"J. Environ. Manage."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1017\/ice.2016.174","article-title":"Antimicrobial-Resistant Pathogens Associated with Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network at the Centers for Disease Control and Prevention, 2011\u20132020","volume":"37","author":"Weiner","year":"2016","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1306801","article-title":"Emerging Infections Program Healthcare-Associated Infections and Antimicrobial Use Prevalence Survey Team. Multistate Point-Prevalence Survey of Health Care-Associated Infections","volume":"370","author":"Magill","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.diagmicrobio.2018.04.012","article-title":"Antimicrobial Susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa Isolates from United States Medical Centers Stratified by Infection Type: Results from the International Network for Optimal Resistance Monitoring (INFORM) Surveillance Program, 2015\u20132020","volume":"92","author":"Sader","year":"2018","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"ref_7","unstructured":"CDC (2024, September 28). Antimicrobial Resistance Threats in the United States, 2021\u20132022, Available online: https:\/\/www.cdc.gov\/antimicrobial-resistance\/media\/pdfs\/antimicrobial-resistance-threats-update-2022-508.pdf."},{"key":"ref_8","unstructured":"CDC (2024, September 28). Antibiotic Resistance Threats in the United States, Available online: https:\/\/www.cdc.gov\/antimicrobial-resistance\/media\/pdfs\/2019-ar-threats-report-508.pdf."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"S17","DOI":"10.1093\/cid\/ciaa1581","article-title":"National Estimates of Healthcare Costs Associated with Multidrug-Resistant Bacterial Infections Among Hospitalized Patients in the United States","volume":"72","author":"Nelson","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_10","first-page":"1","article-title":"Antimicrobial-Resistant Pathogens Associated with Adult Healthcare-Associated Infections: Summary of Data Reported to the National Healthcare Safety Network, 2015\u20132020","volume":"41","author":"Abner","year":"2020","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1086\/518460","article-title":"Microbiology of Ventilator\u2013Associated Pneumonia Compared with That of Hospital-Acquired Pneumonia","volume":"28","author":"Weber","year":"2007","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1378\/chest.10-0166","article-title":"Pneumonia Due to Pseudomonas aeruginosa","volume":"139","author":"Fujitani","year":"2011","journal-title":"Chest"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1086\/339488","article-title":"Pseudomonas aeruginosa Ventilator-Associated Pneumonia: Comparison of Episodes Due to Piperacillin-Resistant versus Piperacillin-Susceptible Organisms","volume":"34","author":"Trouillet","year":"2002","journal-title":"Clin. Infect. Dis."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1002\/jhm.899","article-title":"Resistance to Empiric Antimicrobial Treatment Predicts Outcome in Severe Sepsis Associated with Gram-negative Bacteremia","volume":"6","author":"Micek","year":"2011","journal-title":"J. Hosp. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1128\/AAC.49.2.760-766.2005","article-title":"Bloodstream Infections Caused by Antibiotic-Resistant Gram-Negative Bacilli: Risk Factors for Mortality and Impact of Inappropriate Initial Antimicrobial Therapy on Outcome","volume":"49","author":"Kang","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e02671-16","DOI":"10.1128\/AAC.02671-16","article-title":"Results from a 13-Year Prospective Cohort Study Show Increased Mortality Associated with Bloodstream Infections Caused by Pseudomonas aeruginosa Compared to Other Bacteria","volume":"61","author":"Thaden","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e01759-19","DOI":"10.1128\/AAC.01759-19","article-title":"Predictors of Mortality in Bloodstream Infections Caused by Pseudomonas aeruginosa and Impact of Antimicrobial Resistance and Bacterial Virulence","volume":"64","author":"Recio","year":"2020","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1016\/j.ajic.2016.08.007","article-title":"International Nosocomial Infection Control Consortium Report, Data Summary of 50 Countries for 2010\u20132015: Device-Associated Module","volume":"44","author":"Rosenthal","year":"2016","journal-title":"Am. J. Infect. Control"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.jiph.2009.08.003","article-title":"Urinary Tract Infections Caused by Pseudomonas aeruginosa: A Minireview","volume":"2","author":"Mittal","year":"2009","journal-title":"J. Infect. Public Health"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Moon, C., Kang, J.S., Mun, S.J., Kim, S.-H., and Wi, Y.M. (2024). Long-Term Outcomes of Multidrug-Resistant Pseudomonas aeruginosa Bacteriuria: A Retrospective Cohort Study. Antibiotics, 13.","DOI":"10.3390\/antibiotics13080685"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1763","DOI":"10.1007\/s13304-022-01243-3","article-title":"Surgical Site Infections Caused by Multi-Drug Resistant Organisms: A Case\u2013Control Study in General Surgery","volume":"74","author":"Foschi","year":"2022","journal-title":"Updat. Surg."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Bhagirath, A.Y., Li, Y., Somayajula, D., Dadashi, M., Badr, S., and Duan, K. (2016). Cystic Fibrosis Lung Environment and Pseudomonas aeruginosa Infection. BMC Pulm. Med., 16.","DOI":"10.1186\/s12890-016-0339-5"},{"key":"ref_23","unstructured":"Cystic Fibrosis Foundation Patient Registry (2021). 2021 Annual Datal Report, Cystic Fibrosis Foundation Patient Registry."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1089\/sur.2013.134","article-title":"Infection in Burns","volume":"17","author":"Norbury","year":"2016","journal-title":"Surg. Infect."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"R183","DOI":"10.1186\/cc8170","article-title":"The Leading Causes of Death after Burn Injury in a Single Pediatric Burn Center","volume":"13","author":"Williams","year":"2009","journal-title":"Crit. Care"},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Azzopardi, E.A., Azzopardi, E., Camilleri, L., Villapalos, J., Boyce, D.E., Dziewulski, P., Dickson, W.A., and Whitaker, I.S. (2014). Gram Negative Wound Infection in Hospitalised Adult Burn Patients-Systematic Review and Metanalysis-. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0095042"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1086\/376993","article-title":"The Epidemiology of Burn Wound Infections: Then and Now","volume":"37","author":"Weinstein","year":"2003","journal-title":"Clin. Infect. Dis."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Abdi, F.A., Motumma, A.N., Kalayu, A.A., and Abegaz, W.E. (2024). Prevalence and Antimicrobial-Resistant Patterns of Pseudomonas aeruginosa among Burn Patients Attending Yekatit 12 Hospital Medical College in Addis Ababa, Ethiopia. PLoS ONE, 19.","DOI":"10.1371\/journal.pone.0289586"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/S0305-4179(98)00090-4","article-title":"Pseudomonas Infections in Tohid Burn Center, Iran","volume":"24","author":"Alaghehbandan","year":"1998","journal-title":"Burns"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"100764","DOI":"10.1016\/j.nmni.2020.100764","article-title":"Epidemiology of Burn Wound Bacterial Infections at a Meknes Hospital, Morocco","volume":"38","author":"Barguigua","year":"2020","journal-title":"New Microbes New Infect."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s40121-019-0232-7","article-title":"Microbial Epidemiology of Infectious Endocarditis in the Intravenous Drug Abuse Population: A Retrospective Study","volume":"8","author":"Lorson","year":"2019","journal-title":"Infect. Dis. Ther."},{"key":"ref_32","unstructured":"Bennett, J.E., Dolin, R., and Blaser, M.J. (2020). Pseudomonas aeruginosa and Other Pseudomonas Species. Mandell, Douglas, and Bennett\u2019s Principles and Practice of Infectious Diseases, Elsevier."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3201\/eid0802.010121","article-title":"Multidrug-Resistant Pseudomonas aeruginosa Bloodstream Infections: Analysis of Trends in Prevalence and Epidemiology","volume":"8","author":"Tacconelli","year":"2002","journal-title":"Emerg. Infect. Dis."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"e13186","DOI":"10.1111\/tid.13186","article-title":"Contribution of Specific Pathogens to Bloodstream Infection Mortality in Neutropenic Patients with Hematologic Malignancies: Results from a Multicentric Surveillance Cohort Study","volume":"21","author":"Kern","year":"2019","journal-title":"Transpl. Infect. Dis."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.cmi.2019.07.002","article-title":"Predictors of Multidrug-Resistant Pseudomonas aeruginosa in Neutropenic Patients with Bloodstream Infection","volume":"26","author":"Viasus","year":"2020","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ijid.2018.03.022","article-title":"Bloodstream Infections in Cancer Patients. Risk Factors Associated with Mortality","volume":"71","year":"2018","journal-title":"Int. J. Infect. Dis."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1111\/j.1399-3062.2009.00380.x","article-title":"Pseudomonas aeruginosa Bacteremia over a 10-year Period: Multidrug Resistance and Outcomes in Transplant Recipients","volume":"11","author":"Johnson","year":"2009","journal-title":"Transpl. Infect. Dis."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/j.1399-0012.2009.01184.x","article-title":"Risk Factors for Pneumonia Caused by Multidrug-resistant Gram-negative Bacilli among Liver Recipients","volume":"24","author":"Shi","year":"2010","journal-title":"Clin. Transplant."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1016\/j.transproceed.2010.07.082","article-title":"Epidemiology of Pneumonia in Kidney Transplantation","volume":"42","author":"Hoyo","year":"2010","journal-title":"Transplant. Proc."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1701190","DOI":"10.1183\/13993003.01190-2017","article-title":"Burden and Risk Factors for Pseudomonas aeruginosa Community-Acquired Pneumonia: A Multinational Point Prevalence Study of Hospitalised Patients","volume":"52","author":"Restrepo","year":"2018","journal-title":"Eur. Respir. J."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"3969","DOI":"10.1128\/AAC.02467-12","article-title":"Bacterial and Clinical Characteristics of Health Care- and Community-Acquired Bloodstream Infections Due to Pseudomonas aeruginosa","volume":"57","author":"Hattemer","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e183927","DOI":"10.1001\/jamanetworkopen.2018.3927","article-title":"Development and Assessment of Risk Scores for Carbapenem and Extensive \u03b2-Lactam Resistance Among Adult Hospitalized Patients with Pseudomonas aeruginosa Infection","volume":"1","author":"Tartof","year":"2018","journal-title":"JAMA Netw. Open"},{"key":"ref_43","first-page":"1788","article-title":"Novel Pseudomonas aeruginosa Scoring System to Guide Empiric Anti-Pseudomonal Therapy in COPD Patients with Community-Acquired Pneum\u00f2nia","volume":"56","author":"Amati","year":"2020","journal-title":"Eur. Respir. J."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s13756-018-0370-9","article-title":"Risk Factors for Hospitalized Patients with Resistant or Multidrug-Resistant Pseudomonas aeruginosa Infections: A Systematic Review and Meta-Analysis","volume":"7","author":"Raman","year":"2018","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"ref_45","first-page":"295","article-title":"Flagellar and Twitiching Motility Are Necessary for Pseudomonas aeruginosa Biofilm Development","volume":"30","author":"Kolter","year":"1996","journal-title":"Mol. Microbiol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1128\/JB.185.7.2374-2378.2003","article-title":"Biofilm Formation by Hyperpiliated Mutants of Pseudomonas aeruginosa","volume":"185","author":"Chiang","year":"2003","journal-title":"J. Bacteriol."},{"key":"ref_47","doi-asserted-by":"crossref","unstructured":"Hardy, K., Tessmer, M., Frank, D., and Audia, J. (2021). Perspectives on the Pseudomonas aeruginosa Type III Secretion System Effector ExoU and Its Subversion of the Host Innate Immune Response to Infection. Toxins, 13.","DOI":"10.3390\/toxins13120880"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1086\/379372","article-title":"Secretion of the Toxin ExoU Is a Marker for Highly Virulent Pseudomonas aeruginosa Isolates Obtained from Patients with Hospital-Acquired Pneumonia","volume":"188","author":"Schulert","year":"2003","journal-title":"J. Infect. Dis."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.biotechadv.2018.11.013","article-title":"Antibiotic Resistance in Pseudomonas aeruginosa: Mechanisms and Alternative Therapeutic Strategies","volume":"37","author":"Pang","year":"2019","journal-title":"Biotechnol. Adv."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Ledizet, M., Murray, T.S., Puttagunta, S., Slade, M.D., Quagliarello, V.J., and Kazmierczak, B.I. (2012). The Ability of Virulence Factor Expression by Pseudomonas aeruginosa to Predict Clinical Disease in Hospitalized Patients. PLoS ONE, 7.","DOI":"10.1371\/journal.pone.0049578"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Hall, S., McDermott, C., Anoopkumar-Dukie, S., McFarland, A., Forbes, A., Perkins, A., Davey, A., Chess-Williams, R., Kiefel, M., and Arora, D. (2016). Cellular Effects of Pyocyanin, a Secreted Virulence Factor of Pseudomonas aeruginosa. Toxins, 8.","DOI":"10.3390\/toxins8080236"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"261","DOI":"10.2147\/IDR.S144299","article-title":"Exploring Bacterial Outer Membrane Barrier to Combat Bad Bugs","volume":"2017","author":"Ghai","year":"2017","journal-title":"Infect. Drug Resist."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1128\/CMR.00036-08","article-title":"AmpC Beta-Lactamases","volume":"22","author":"Jacoby","year":"2009","journal-title":"Clin. Microbiol. Rev."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1128\/AAC.49.2.479-487.2005","article-title":"Aminoglycoside Resistance in Pseudomonas aeruginosa","volume":"49","author":"Poole","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1128\/AAC.05398-11","article-title":"Mechanisms of Resistance to Chloramphenicol in Pseudomonas Putida KT24","volume":"56","author":"Conde","year":"2012","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1007\/BF01569821","article-title":"Pseudomonas aeruginosa Biofilms: Role of the Alginate Exopolysaccharide","volume":"15","author":"Boyd","year":"1995","journal-title":"J. Ind. Microbiol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.3201\/eid2507.181200","article-title":"Carbapenem-Resistant Pseudomonas aeruginosa at US Emerging Infections Program Sites, 2015","volume":"25","author":"Walters","year":"2019","journal-title":"Emerg. Infect. Dis."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1093\/jac\/dku048","article-title":"Epidemiology and Carbapenem Resistance Mechanisms of Carbapenem-Non-Susceptible Pseudomonas aeruginosa Collected during 2009-11 in 14 European and Mediterranean Countries","volume":"69","author":"Castanheira","year":"2014","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e159","DOI":"10.1016\/S2666-5247(22)00329-9","article-title":"Global Epidemiology and Clinical Outcomes of Carbapenem-Resistant Pseudomonas aeruginosa and Associated Carbapenemases (POP): A Prospective Cohort Study","volume":"4","author":"Reyes","year":"2023","journal-title":"Lancet Microbe"},{"key":"ref_60","doi-asserted-by":"crossref","unstructured":"Tamma, P.D., Heil, E.L., Justo, J.A., Mathers, A.J., Satlin, M.J., and Bonomo, R.A. (2024). Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections. Clin. Infect. Dis., ciae403.","DOI":"10.1093\/cid\/ciae403"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1128\/AAC.00385-10","article-title":"NagZ Inactivation Prevents and Reverts \u03b2-Lactam Resistance, Driven by AmpD and PBP 4 Mutations, in Pseudomonas aeruginosa","volume":"54","author":"Zamorano","year":"2010","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_62","first-page":"568","article-title":"Emerging Broad-Spectrum Resistance in Pseudomonas aeruginosa and Acinetobacter Baumannii: Mechanisms and Epidemiology","volume":"45","author":"Potron","year":"2015","journal-title":"Int. J. Antibiot."},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Laudy, A.E., R\u00f3g, P., Smoli\u0144ska-Kr\u00f3l, K., \u0106miel, M., S\u0142oczy\u0144ska, A., Patzer, J., Dzier\u017canowska, D., Wolinowska, R., Staro\u015bciak, B., and Tyski, S. (2017). Prevalence of ESBL-Producing Pseudomonas aeruginosa Isolates in Warsaw, Poland, Detected by Various Phenotypic and Genotypic Methods. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0180121"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Fang, Z.-L., Zhang, L.-Y., Huang, Y.-M., Qing, Y., Cao, K.-Y., Tian, G.-B., and Huang, X. (2014). OprD Mutations and Inactivation in Imipenem-Resistant Pseudomonas aeruginosa Isolates from China. Infect. Genet. Evol., 21.","DOI":"10.1016\/j.meegid.2013.10.027"},{"key":"ref_65","doi-asserted-by":"crossref","unstructured":"LaBauve, A., and Wargo, M. (2012). Growth and Laboratory Maintenance of Pseudomonas aeruginosa. Curr. Protoc. Microbiol.","DOI":"10.1002\/9780471729259.mc06e01s25"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"481","DOI":"10.4103\/0971-5916.159308","article-title":"Performance of Extended Spectrum Beta Lactamases (ESBL) Screening Agar in Various Clinical Specimens","volume":"141","author":"Swarna","year":"2015","journal-title":"Indian J. Med. Res."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Boutal, H., Moguet, C., Pommi\u00e8s, L., Simon, S., Naas, T., and Volland, H. (2022). The Revolution of Lateral Flow Assay in the Field of AMR Detection. Diagn. Basel., 12.","DOI":"10.3390\/diagnostics12071744"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Welker, M., and Belkum, A. (2019). van One System for All: Is Mass Spectrometry a Future Alternative for Conventional Antibiotic Susceptibility Testing?. Front. Microbiol., 10.","DOI":"10.3389\/fmicb.2019.02711"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s40265-013-0168-2","article-title":"Ceftolozane\/Tazobactam: A Novel Cephalosporin\/\u03b2-Lactamase Inhibitor Combination with Activity Against Multidrug-Resistant Gram-Negative Bacilli","volume":"74","author":"Zhanel","year":"2014","journal-title":"Drugs"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1007\/s40121-022-00591-2","article-title":"Therapeutic Strategies for Emerging Multidrug-Resistant Pseudomonas aeruginosa","volume":"11","author":"Holger","year":"2022","journal-title":"Infect. Dis. Ther."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","article-title":"Ceftolozane-Tazobactam Compared with Levofloxacin in the Treatment of Complicated Urinary-Tract Infections, Including Pyelonephritis: A Randomised, Double-Blind, Phase 3 Trial (ASPECT-cUTI)","volume":"385","author":"Wagenlehner","year":"2015","journal-title":"Lancet Lond. Engl."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/cid\/civ097","article-title":"Ceftolozane\/Tazobactam Plus Metronidazole for Complicated Intra-Abdominal Infections in an Era of Multidrug Resistance: Results from a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)","volume":"60","author":"Solomkin","year":"2015","journal-title":"Clin. Infect. Dis."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","article-title":"Ceftolozane-Tazobactam versus Meropenem for Treatment of Nosocomial Pneumonia (ASPECT-NP): A Randomised, Controlled, Double-Blind, Phase 3, Non-Inferiority Trial","volume":"19","author":"Kollef","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s40265-013-0013-7","article-title":"Ceftazidime-Avibactam: A Novel Cephalosporin\/\u03b2-Lactamase Inhibitor Combination","volume":"73","author":"Zhanel","year":"2013","journal-title":"Drugs"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/S1473-3099(16)30004-4","article-title":"Ceftazidime-Avibactam or Best Available Therapy in Patients with Ceftazidime-Resistant Enterobacteriaceae and Pseudomonas aeruginosa Complicated Urinary Tract Infections or Complicated Intra-Abdominal Infections (REPRISE): A Randomised, Pathogen-Directed, Phase 3 Study","volume":"16","author":"Carmeli","year":"2016","journal-title":"Lancet Infect. Dis."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1093\/cid\/ciw133","article-title":"Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-Abdominal Infection: Results from a Randomized, Controlled, Double-Blind, Phase 3 Program","volume":"62","author":"Mazuski","year":"2016","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/S1473-3099(17)30747-8","article-title":"Ceftazidime-Avibactam versus Meropenem in Nosocomial Pneumonia, Including Ventilator-Associated Pneumonia (REPROVE): A Randomised, Double-Blind, Phase 3 Non-Inferiority Trial","volume":"18","author":"Torres","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s40265-017-0851-9","article-title":"Imipenem\u2013Relebactam and Meropenem\u2013Vaborbactam: Two Novel Carbapenem-\u03b2-Lactamase Inhibitor Combinations","volume":"78","author":"Zhanel","year":"2018","journal-title":"Drugs"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Young, K., Painter, R.E., Raghoobar, S.L., Hairston, N.N., Racine, F., Wisniewski, D., Balibar, C.J., Villafania, A., Zhang, R., and Sahm, D.F. (2019). In Vitro Studies Evaluating the Activity of Imipenem in Combination with Relebactam against Pseudomonas aeruginosa. BMC Microbiol., 19.","DOI":"10.1186\/s12866-019-1522-7"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1093\/cid\/ciz530","article-title":"RESTORE-IMI 1: A Multicenter, Randomized, Double-Blind Trial Comparing Efficacy and Safety of Imipenem\/Relebactam vs Colistin Plus Imipenem in Patients with Imipenem-Nonsusceptible Bacterial Infections","volume":"70","author":"Motsch","year":"2020","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e4539","DOI":"10.1093\/cid\/ciaa803","article-title":"A Randomized, Double-Blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem\/Cilastatin\/Relebactam Versus Piperacillin\/Tazobactam in Adults with Hospital-Acquired or Ventilator-Associated Bacterial Pneumonia (RESTORE-IMI 2 Study)","volume":"73","author":"Titov","year":"2020","journal-title":"Clin. Infect. Dis. Off. Publ. Infect. Dis. Soc. Am."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"4856","DOI":"10.1128\/AAC.00843-15","article-title":"Activity of Meropenem Combined with RPX7009, a Novel \u03b2-Lactamase Inhibitor, against Gram-Negative Clinical Isolates in New York City","volume":"59","author":"Lapuebla","year":"2015","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"ofab371","DOI":"10.1093\/ofid\/ofab371","article-title":"Real-World, Multicenter Experience with Meropenem-Vaborbactam for Gram-Negative Bacterial Infections Including Carbapenem-Resistant Enterobacterales and Pseudomonas aeruginosa","volume":"8","author":"Alosaimy","year":"2021","journal-title":"Open Forum Infect. Dis."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1001\/jama.2018.0438","article-title":"Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection","volume":"319","author":"Kaye","year":"2018","journal-title":"JAMA"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1007\/s40121-018-0214-1","article-title":"Effect and Safety of Meropenem\u2013Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial","volume":"7","author":"Wunderink","year":"2018","journal-title":"Infect. Dis. Ther."},{"key":"ref_86","unstructured":"Fetroja (2024, September 28). Package Insert. Shionogi, Available online: https:\/\/www.shionogi.com\/content\/dam\/shionogi\/si\/products\/pdf\/fetroja.pdf."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/S1473-3099(18)30554-1","article-title":"Cefiderocol versus Imipenem-Cilastatin for the Treatment of Complicated Urinary Tract Infections Caused by Gram-Negative Uropathogens: A Phase 2, Randomised, Double-Blind, Non-Inferiority Trial","volume":"18","author":"Portsmouth","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref_88","unstructured":"Bassetti, M. (2024, September 30). Efficacy and Safety of Cefiderocol or Best Available Therapy for the Treatment of Serious Infections Caused by Carbapenem-Resistant Gram-Negative Bacteria (CREDIBLE-CR): A Randomised, Open-Label, Multicentre, Pathogen-Focused, Descriptive, Phase 3 Trial\u2014ClinicalKey. Available online: https:\/\/www.clinicalkey.com\/#!\/content\/playContent\/1-s2.0-S1473309920307969?returnurl=null&referrer=null."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus High-Dose, Extended-Infusion Meropenem for the Treatment of Gram-Negative Nosocomial Pneumonia (APEKS-NP): A Randomised, Double-Blind, Phase 3, Non-Inferiority Trial","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"e0217120","DOI":"10.1128\/AAC.02171-20","article-title":"New Perspectives on Antimicrobial Agents: Cefiderocol","volume":"65","author":"McCreary","year":"2021","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jinf.2014.03.001","article-title":"Colistin in Multi-Drug Resistant Pseudomonas aeruginosa Blood-Stream Infections","volume":"69","author":"Martis","year":"2014","journal-title":"J. Infect."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Jeannot, K., Hagart, K., Dortet, L., Kostrzewa, M., Filloux, A., Plesiat, P., and Larrouy-Maumus, G. (2021). Detection of Colistin Resistance in Pseudomonas aeruginosa Using the MALDIxin Test on the Routine MALDI Biotyper Sirius Mass Spectrometer. Front. Microbiol., 12.","DOI":"10.3389\/fmicb.2021.725383"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jgar.2022.01.023","article-title":"Ceftolozane-Tazobactam vs. Colistin for the Treatment of Infections Due to Multidrug-Resistant Pseudomonas aeruginosa: A Multicentre Cohort Study","volume":"28","author":"Almangour","year":"2022","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"ref_94","unstructured":"(2024, October 01). Karakonstantis Treatment Options for K. Pneumoniae, P. aeruginosa and A. Baumannii Co-Resistant to Carbapenems, Aminoglycosides, Polymyxins and Tigecycline: An Approach Based on the Mechanisms of Resistance to Carbapenems\u2014PMC, Available online: https:\/\/www-ncbi-nlm-nih-gov.proxy.lib.wayne.edu\/pmc\/articles\/PMC7461763\/."},{"key":"ref_95","first-page":"259","article-title":"Murepavadin: A New Antibiotic Class in the Pipeline","volume":"16","author":"Dale","year":"2017","journal-title":"Expert Rev. Anti Infect. Ther."}],"container-title":["Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-0817\/13\/11\/975\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T16:28:20Z","timestamp":1760113700000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-0817\/13\/11\/975"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,7]]},"references-count":95,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2024,11]]}},"alternative-id":["pathogens13110975"],"URL":"https:\/\/doi.org\/10.3390\/pathogens13110975","relation":{},"ISSN":["2076-0817"],"issn-type":[{"value":"2076-0817","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,7]]}}}